Education

Timely Topics in Transplantation Webinar Series

September 20, 2018

Speaker: David H. Sachs, MD • CUMC & MGH/HMS
Moderator: Sebastian Eriksson Giwa, PhD • Ossium Health and Sylvatica Biotech

After participating in this webinar, the learner will be able to:

  1. Explain the advantages of tolerance vs. immune suppression.
  2. Evaluate the overall status of clinical transplant tolerance and the protocols used in trials.
  3. Identify current limitations to immune tolerance protocols.
  4. Identify potential solutions through the use of organ and cell preservation technologies.
  5. Evaluate the protocols in trials and the overall status of clinical transplant tolerance.

Archive coming soon.

September 12, 2018

View Archive

Speaker: Andrew Wells, PhD • University of Pennsylvania and CHOP
Moderator: Jonathan Maltzman, MD, PhD • Stanford University

After participating in this webinar, the learner will be able to:

  1. Define epigenetics, outline basic concepts and processes.
  2. Outline examples of DNA methylation controlling T cell function.
  3. Outline examples of histone modifications controlling T cell function.
  4. Describe examples of epigenetic factors contributing to organ transplant rejection in rodent models.
  5. Describe a clinical example of epigenetic drug targeting in allogenic bone marrow transplantation to alleviate GVHD.
  6. Outline basic concepts in genomics and epigenomics.
  7. Describe 3-dimensional regulatory architectures of inflammatory genes in T cells.
  8. Discuss the use of 3D epigenomics to understand the basis of genetic susceptibility to inflammatory disease in humans.
June 21, 2018

View Archive

Speaker: Cynthia Fisher, MD, MPH • University of Washington
Moderator: Sangeeta Bhorade, MD • Northwestern University

After participating in this webinar, the learner will be able to:

  1. Describe the incidence and clinical impact of respiratory viruses (RVs) in lung transplant recipients (LTR).
  2. Explain the evidence linking RVI to chronic lung allograft dysfunction (CLAD).
  3. List currently available and promising investigational therapies for: RSV, Influenza, and PIV.
  4. Discuss prevention strategies.
February 07, 2018

View Archive

Speakers:
Hans H. Hirsch, MD, MSc • University of Basel
Oriol Bestard, MD, PhD • Bellvitge University Hospital, IDIBELL
Olivia M. Martinez, PhD • Stanford University School of Medicine

Moderator:
Lara Danziger-Isakov, MD, MPH • Cincinnati Children's Hospital Medical Center

After participating in this webinar, the learner will be able to:

  1. Describe the limitations of current viral assays to diagnose CMV, EBV, and BK polyomavirus.
  2. Discuss the emerging diagnostic testing including host responses for CMV and BK polyoma virus.
  3. Describe the emerging concepts of the immune response to EBV that permit transition from infection to Post-Transplant Lymphoproliferative Disease.
March 21, 2018

View Archive

View additional resources

Speaker: Gwen McNatt, PhD, MS, CNN • Northwestern Memorial Hospital
Moderator: Marian O'Rourke, RN, CCTC • Jackson Memorial Hospital

After participating in this webinar, the learner will be able to:

  1. Describe at least two change models and how to apply them.
  2. Discuss change readiness and how to assess readiness.
  3. Discuss the change curve during implementation of a change.
  4. Describe strategies to sustain change.

Change management is a leadership concept/strategy to lead and embed positive change in organizations and groups.  This is often part of any successful performance improvement process. 

February 21, 2018

View Archive

Speaker: Lara Danziger-Isakov, MD, MPH • Cincinnati Children's Hospital Medical Center
Moderator: Deepali Kumar, MD  • University Health Network

After participating in this webinar, the learner will be able to:

  1. Describe the currently recommended evaluation and administration of vaccination in the solid organ transplant candidate.
  2. Discuss considerations for vaccination in solid organ transplant recipients including timing and responses.
  3. Recognize the considerations for live-viral vaccination before and after solid organ transplantation, including newly available vaccinations.
January 18, 2018

View Archive

Read the Q&A not answered during the webinar

Speaker: Ronald Gill, PhD • University of Colorado - Denver
Moderator: Leonardo Riella, MD, PhD, FASN, FAST • Brigham and Women's Hospital

After participating in this webinar, the learner will be able to:

  1. Describe current concerns in biomedical research about the reliability of pre-clinical studies using small animal models.
  2. Convey the potential impact of publication bias in pre-clinical research.
  3. Illustrate the use of multi-center pre-clinical studies.
  4. Suggest guidelines about conducting pre-clinical research.
December 05, 2017

View Archive

Read the Q&A not answered during webinar

Speaker: Francisco Marty, MD • Brigham and Women's Hospital
Moderator: Leonardo Riella, MD, PhD, FASN, FAST • Brigham and Women's Hospital

After participating in this webinar, the learner will be able to:

  1. Describe the most common invasive fungal infections post-transplantation.
  2. Define the available diagnostic tests and upcoming assays for fungal infection.
  3. Summarize the new anti-fungal therapies and side effects.
November 14, 2017

View Archive

Speaker: Jon Kobashigawa, MD • Cedars Sinai Heart Institute
Moderator: Sean Pinney, MD • Mount Sinai School of Medicine

After participating in this webinar, the learner will be able to: 

  1. Relate the advances in immunosuppression therapy.
  2. Describe the mechanisms of immunosuppression.
  3. Identify the newer immunosuppression agents and future therapies.
October 17, 2017

View Archive

Read the Q&A not answered during webinar

Speaker: Martha Pavlakis, MD • Beth Israel Deaconess Medical Center
Moderator: Tarek Alhamad, MD • Washington University School of Medicine in St. Louis

After participating in this webinar, the learner will be able to:

  1. Identify the challenges in managing the kidney transplant patient with a failing allograft.
  2. Describe the increased risks of death and sepsis for the allograft recipient as they return to dialysis.
  3. Discuss the options for managing immunosuppression and end stage rejection in the failed allograft.

Pages